Talphera (TLPH) announced the enrollment of 17 patients in its 70-patient pivotal NEPHRO CRRT clinical trial. The enrollment of 17 patients is a milestone that was required to be achieved, and announced, as one of the conditions to close the second tranche of the three-tranche financing announced in March 2025. The company is on track for planned study completion by the end of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPH:
- Positive Outlook for Talphera: Buy Rating Backed by Promising Niyad Trial Progress and Strong Financial Position
- Talphera Reports Q2 2025 Financial Results and Study Progress
- Talphera reports Q2 EPS (10c) vs. (15c) last year
- Talphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19M